
Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.
October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs
October delivered a slew of significant developments in nephrology, underscoring rapid momentum in both therapeutic innovation and clinical guidance. The month was highlighted by a landmark US Food and Drug Administration (FDA) approval in lupus nephritis for obinutuzumab, accompanied by new phase 3 data in IgA nephropathy (IgAN), reinforcing continued progress toward more effective, individualized treatment.






